Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure

被引:5
|
作者
Wallhaus, TR
Taylor, M
DeGrado, TR
Russell, DC
Stanko, P
Nickles, RJ
Stone, CK
机构
[1] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA
[2] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA
[3] Duke Univ, Dept Med Phys, Durham, NC USA
[4] Univ Wisconsin, Dept Med, Madison, WI USA
关键词
fatty acids; glucose; metabolism; heart failure;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Use of beta -adrenoreceptor blockade in the treatment of heart failure has been associated with a reduction in myocardial oxygen consumption and an improvement in myocardial energy efficiency. One potential mechanism for this beneficial effect is a shift in myocardial substrate use from increased free fatty acid (FFA) oxidation to increased glucose oxidation, Methods and Results-We studied the effect of carvedilol therapy on myocardial FFA and glucose use in 9 patients with stable New York Heart Association functional class III ischemic cardiomyopathy (left ventricular ejection fraction less than or equal to 35%) using myocardial positron emission tomography studies and resting echocardiograms before and 3 months after carvedilol treatment. Myocardial uptake of the novel long chain fatty acid metabolic tracer 14(R, S)-[F-18]fluoro-6-thiaheptadecanoic acid ([F-18]-FTHA) was used to determine myocardial FFA use, and [F-18] fluoro-2-deoxy-glucose ([F-18]-FDG) was used to determine myocardial glucose use. After carvedilol treatment, the mean myocardial uptake rate for [F-18]-FTHA decreased (from 20.4+/-8.6 to 9.7+/-2.3 ml . 100 g(-1) . min(-1); P<0.005), mean fatty acid use decreased (from 19.3+/-7.0 to 8.2+/-1.8 <mu>moL . 100 g(-1) . min(-1); P<0.005), the mean myocardial uptake rate for [F-18]-FDG was unchanged (from 1.4+/-0.4 to 2.4+/-0.8 mL . 100 g(-1) . min(-1); P=0.14), and mean glucose use was unchanged (from 11.1+/-3.1 to 18.7+/-6.0 <mu>moL . 100 g(-1) . min(-1); P=0.12), Serum FFA and glucose concentrations were unchanged, and mean left ventricular ejection fraction improved (from 26+/-2% to 37+/-4%; P<0.05), Conclusions-Carvedilol treatment in patients with heart failure results in a 57% decrease in myocardial FFA use without a significant change in glucose use. These metabolic changes could contribute to the observed improvements in energy efficiency seen in patients with heart failure.
引用
收藏
页码:2441 / 2446
页数:6
相关论文
共 50 条
  • [31] Heart type fatty acid binding protein (hFABP) in patients with acute congestive heart failure
    Behnes, M.
    Espeter, F. E.
    Lang, S. L.
    Ahmad-Nejad, P. A. N.
    Neumaier, M. N.
    Brueckmann, M. B.
    Borggrefe, M. B.
    Hoffmann, U. H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 485 - 486
  • [32] Heart Type Fatty Acid Binding Protein (hFABP) in Patients with Acute Congestive Heart Failure
    Behnes, Michael
    Espeter, Florian
    Lang, Siegfried
    Ahmad-Nejad, Parviz
    Neumaier, Michael
    Brueckmann, Martina
    Borggrefe, Martin
    Hoffmann, Ursula
    CIRCULATION, 2012, 126 (21)
  • [33] Use of Spironolactone in the Treatment of Congestive Heart Failure
    Jean, Lachaine
    Catherine, Beauchemin
    Elodie, Ramos
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S132 - S132
  • [35] Effect of carvedilol on myocardial perfusion in patients with chronic heart failure
    Kamilova, U.
    Jurayeva, S. H.
    Aliyeva, T.
    Kevorkov, A.
    Myasnik, B.
    CIRCULATION, 2008, 118 (12) : E231 - E232
  • [36] Carvedilol reduces prolonged QT interval dispersion in congestive heart failure patients
    Chinaglia, A
    Gaschino, G
    Tidu, M
    Coda, L
    Veglio, M
    Ghisio, A
    Trinchero, R
    EUROPEAN HEART JOURNAL, 2000, 21 : 411 - 411
  • [37] Carvedilol therapy is associated with improvement in QT dispersion in patients with congestive heart failure
    Sevimli, Serdar
    Arslan, Sakir
    Gundogdu, Fuat
    Aksakal, Enbiya
    Tas, Hakan
    Gurlertop, Yekta
    Senocak, Huseyin
    Atesal, Sebahattin
    Alp, Necip
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2007, 35 (05): : 284 - 288
  • [38] The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure
    Yildirir, A
    Sade, E
    Tokgozoglu, L
    Oto, A
    EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (06) : 717 - 721
  • [39] Carvedilol Improves Uptake-1 in Patients With Systolic Congestive Heart Failure
    Machida, Maiko
    Takechi, Shigeru
    Fujimoto, Tetsuya
    Kakinoki, Shigeo
    Nomura, Akikazu
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2012, 59 (02) : 175 - 181
  • [40] Carvedilol administration improves ventricular electrophysiological properties in congestive heart failure patients
    Kanoupakis, E. M.
    Mavrakis, H. E.
    Kallergis, E. M.
    Kafarakis, P. K.
    Nyktaris, E. G.
    Melessanakis, M. H.
    Manios, E. G.
    Vardas, P. E.
    EUROPEAN HEART JOURNAL, 2005, 26 : 74 - 74